Table 3.
OS with respect to the treatment arms
| Treatment arm | Events/Total | HR (95% CI)* | Mean OS at 2yrs (in months) | KM Survival Estimate** | P value*** | |
|---|---|---|---|---|---|---|
| DAEPOCH | 9/23 | 0.43, (0.20–0.92) | 28.1 | At 1 yr | 0.95 (0.76–0.99) | 0.03 |
| At 2 yr | 0.60 (0.38–0.79) | |||||
| At 3 yr | 0.60 (0.38–0.79) | |||||
| CHOP | 27/34 | Reference | 20.7 | At 1 yr | 0.91 (0.75–0.97) | |
| At 2 yr | 0.20 (0.09–0.38) | |||||
| At 3 yr | 0.20 (0.09–0.38) | |||||
| Over all | 36/57 | 24.5 | At 1 yr | 0.92 (0.82–0.97) | ||
| At 2 yr | 0.36 (0.24–0.50) | |||||
| At 3 yr | 0.36 (0.24–0.50) | |||||
OS, Overall Survival; DAEPOCH, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone
*Cox model
**Kaplan–Meier method
***Log-rank test